Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

The third quarter of 2024 brought a mix of gains and modest declines for the pharmaceutical industry’s top players ... Among ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

Nov 6 (Reuters) - Gilead Sciences (GILD.O), opens new tab reported third-quarter financial results that handily beat Wall ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

Regeneron Pharmaceuticals and Amgen, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance. Gilead ...

Stringer covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Gilead Sciences, and Apellis Pharmaceuticals. According to TipRanks, Stringer has an average return of 7.5% ...

Deadly fungi including Candida auris have been spreading. Gilead and Merck are two pharma stocks worth owning amidst fungal ...

and Gilead Sciences. According to TipRanks, Abrahams has an average return of 5.4% and a 48.10% success rate on recommended stocks. Currently, the analyst consensus on Corbus Pharmaceuticals is a ...

The consensus rating for Gilead Sciences is Neutral, based on 16 analyst ratings. With an average one-year price target of $84.25, there's a potential 6.22% downside.